Key result
Genetic proxies for CCB targets are linked to a slightly higher risk of asthma.
Why the study?
The study investigated whether genetically proxied modulation of antihypertensive drug targets is associated with autoimmune disease risk.
Does genetically proxied modulation of antihypertensive drug targets affect autoimmune disease risk in individuals of European ancestry?
Observational
Does genetically proxied modulation of antihypertensive drug targets affect autoimmune disease risk in individuals of European ancestry?
This Mendelian randomization study provides hypothesis-generating genetic evidence linking antihypertensive drug targets to minor variations in autoimmune disease risk, though effect sizes are too small to warrant changes in clinical prescribing practices.
Answers are grounded in this paper and cite their sources.
No prescribing changes indicated by tiny effect; leaves open CCB target effects on autoimmune disease.
OBJECTIVE: To investigate whether genetically proxied modulation of antihypertensive drug targets is associated with autoimmune disease risk using drug-target Mendelian Randomization (MR) analysis. METHODS: Genetic proxies for antihypertensive drug targets were selected from systolic blood pressure genome-wide association studies. For targets represented by multiple Single Nucleotide Polymorphisms (SNPs), Inverse-Variance Weighted (IVW) analysis was used as the primary estimator, with weighted median, MR-Egger, and MR-PRESSO analyses performed as complementary and sensitivity analyses. The Wald ratio was used for targets represented by a single SNP. Coronary artery disease was included as a positive- control outcome. A Bonferroni-corrected threshold was applied for multiple testing, with p < 0.00125 considered strong evidence and 0.00125 ≤ p < 0.05 considered suggestive evidence. RESULTS: Using European ancestry GWAS data, genetic proxies for Calcium Channel Blocker (CCB) targets were associated with a higher risk of asthma (OR = 1.001, 95% confidence interval (CI): 1.001-1.002, p = 2.88×10-5), which was the only autoimmune disease association that met the prespecified Bonferroni-corrected significance threshold. Suggestive associations were observed between genetic proxies for beta-adrenoceptor blocker targets and a lower risk of multiple sclerosis (OR = 0.96, 95% CI: 0.925-0.995, p = 2.16×10-2), CCB targets and a lower risk of type 1 diabetes mellitus (OR = 0.98, 95% CI: 0.968-0.999, p = 4.19×10-2), loop diuretic targets and a lower risk of asthma (OR = 0.997, 95% CI: 0.994-0.999, p = 2.07×10-3), and CCB targets and a higher risk of rheumatoid arthritis (OR = 1.021, 95% CI: 1.006-1.037, p = 7.60×10-3). For multi-SNP analyses, sensitivity analyses did not indicate clear evidence of heterogeneity or horizontal pleiotropy for several of the reported associations. Analyses of angiotensin- converting enzyme inhibitor and angiotensin receptor blocker targets were based on single-SNP instruments and therefore were not amenable to conventional multi- -SNP sensitivity analyses. DISCUSSION: The findings suggest disease-specific associations between genetically proxied antihypertensive drug targets and autoimmune outcomes. These results should be interpreted as genetic evidence of target-related effects rather than direct estimates of clinical treatment effects. In particular, although the CCB-asthma association met the Bonferroni-corrected threshold, its effect size was very small and should not be interpreted as evidence of a clinically important treatment effect. CONCLUSION: This study provides genetic evidence for one Bonferroni-significant target- outcome association and several suggestive associations between genetically proxied antihypertensive drug targets and autoimmune disease risk. These findings should be considered hypothesis-generating, require further replication and functional or pharmacological validation, and do not currently provide sufficient evidence to alter antihypertensive prescribing practices.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) conducted an observational in Autoimmune disease risk associated with antihypertensive drug targets. Genetically proxied modulation of antihypertensive drug targets (calcium channel blockers, beta-adrenoceptor blockers, loop diuretics, ACE inhibitors, ARBs) was evaluated on Asthma risk (the only autoimmune disease association meeting the Bonferroni-corrected significance threshold for calcium channel blocker targets) (OR 1.001, 95% CI 1.001-1.002, p=2.88x10-5). Genetic proxies for calcium channel blocker targets were associated with a slightly higher risk of asthma.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: